CN101084240A - MyD88同型二聚体化抑制剂 - Google Patents

MyD88同型二聚体化抑制剂 Download PDF

Info

Publication number
CN101084240A
CN101084240A CNA2005800437629A CN200580043762A CN101084240A CN 101084240 A CN101084240 A CN 101084240A CN A2005800437629 A CNA2005800437629 A CN A2005800437629A CN 200580043762 A CN200580043762 A CN 200580043762A CN 101084240 A CN101084240 A CN 101084240A
Authority
CN
China
Prior art keywords
pro
compound
gly
group
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800437629A
Other languages
English (en)
Chinese (zh)
Inventor
P·卡米纳蒂
G·加洛
N·范托
V·鲁格吉洛
M·萨斯萨诺
D·马斯特罗雅尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of CN101084240A publication Critical patent/CN101084240A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
CNA2005800437629A 2004-12-20 2005-12-16 MyD88同型二聚体化抑制剂 Pending CN101084240A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04425929.9 2004-12-20
EP04425929 2004-12-20

Publications (1)

Publication Number Publication Date
CN101084240A true CN101084240A (zh) 2007-12-05

Family

ID=34932941

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800437629A Pending CN101084240A (zh) 2004-12-20 2005-12-16 MyD88同型二聚体化抑制剂

Country Status (10)

Country Link
US (1) US20080064643A1 (ja)
EP (1) EP1828246A1 (ja)
JP (1) JP2008524167A (ja)
KR (1) KR20070094802A (ja)
CN (1) CN101084240A (ja)
AU (1) AU2005318226A1 (ja)
BR (1) BRPI0519148A2 (ja)
CA (1) CA2590750A1 (ja)
MX (1) MX2007007259A (ja)
WO (1) WO2006067091A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101745094A (zh) * 2010-01-28 2010-06-23 华中科技大学同济医学院附属同济医院 MyD88拓扑类肽化合物作为免疫抑制剂在医学上的用途
CN103889461A (zh) * 2011-07-18 2014-06-25 肯塔基大学研究基金会 保护细胞免于alu-rna诱导的变性和用于保护细胞的抑制剂

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0323204D0 (en) * 2003-10-03 2003-11-05 Novartis Ag Organic compounds
WO2012047175A1 (en) 2010-10-05 2012-04-12 Kemijski inštitut Fusion polypeptides comprising tir and dimerization domain for modulation of tlr/innate immunity signaling
CN102336720B (zh) 2011-03-02 2016-01-13 华中科技大学 2-氨基噻唑衍生物及制备方法和应用
EP2726634B1 (en) 2011-07-01 2017-02-22 Dana-Farber Cancer Institute, Inc. Discovery of a somatic mutation in myd88 gene in lymphoplasmacytic lymphoma
EP2561873A1 (de) 2011-08-26 2013-02-27 Forschungsverbund Berlin e.V. Strukturmimetika prolinreicher Peptide und ihre Verwendung
US9707235B1 (en) 2012-01-13 2017-07-18 University Of Kentucky Research Foundation Protection of cells from degeneration and treatment of geographic atrophy
WO2013112834A1 (en) * 2012-01-25 2013-08-01 Vanderbilt University Compositions and methods for treating infections
US20130297023A1 (en) * 2012-05-07 2013-11-07 Hee-Jeong Im Sampen Methods and Devices For Treating Intervertebral Disc Disease
PL2920197T3 (pl) * 2012-09-26 2021-09-13 President And Fellows Of Harvard College Peptydy zszywane blokowane proliną i ich zastosowania
EP3044338B1 (en) 2013-09-12 2021-11-24 Dana-Farber Cancer Institute, Inc. Methods for evaluating and treating waldenstrom's macroglobulinemia
US10612095B2 (en) 2013-12-06 2020-04-07 Dana-Farber Cancer Institute, Inc. Methods to distinguish Waldenström's Macroglobulinemia from IgM monoclonal gammopathy of undetermined significance
US9856223B2 (en) 2013-12-13 2018-01-02 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
WO2016092069A1 (de) 2014-12-11 2016-06-16 Forschungsverbund Berlin E.V. Inhibitoren zur hemmung der tumormetastasierung
JP2019069905A (ja) * 2016-02-29 2019-05-09 国立大学法人大阪大学 組織損傷治療剤
EP3448390A1 (en) 2016-04-29 2019-03-06 Dana-Farber Cancer Institute, Inc. Hck as a therapeutic target in myd88 mutated diseases
US10662225B2 (en) 2016-06-07 2020-05-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Backbone cyclized inhibitory peptides of myeloid differentiation factor 88 (MyD88)
WO2019051327A2 (en) 2017-09-07 2019-03-14 Fog Pharmaceuticals, Inc. BETA CATENIN FUNCTIONALIZATION AGENTS AND ASSOCIATED METHODS
KR20200134212A (ko) * 2018-01-02 2020-12-01 러쉬 유니버시티 메디컬 센터 신경계 장애 및 기타 장애를 치료하기 위한 조성물 및 방법
WO2024096677A1 (ko) * 2022-11-03 2024-05-10 한국과학기술연구원 Tlr 신호 억제 펩타이드 및 이를 포함하는 염증성 질환의 예방 또는 치료용 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004536585A (ja) 2001-05-09 2004-12-09 エール・ユニバーシティ トル／インターロイキン−１受容体アダプタータンパク質（ｔｉｒａｐ）
AU2002366331A1 (en) * 2001-12-17 2003-06-30 Cedars-Sinai Medical Center Treating vascular disease by inhibiting myeloid differentiation factor 88

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101745094A (zh) * 2010-01-28 2010-06-23 华中科技大学同济医学院附属同济医院 MyD88拓扑类肽化合物作为免疫抑制剂在医学上的用途
CN103889461A (zh) * 2011-07-18 2014-06-25 肯塔基大学研究基金会 保护细胞免于alu-rna诱导的变性和用于保护细胞的抑制剂
CN103889461B (zh) * 2011-07-18 2016-11-09 肯塔基大学研究基金会 保护细胞免于alu-rna诱导的变性和用于保护细胞的抑制剂

Also Published As

Publication number Publication date
EP1828246A1 (en) 2007-09-05
AU2005318226A1 (en) 2006-06-29
MX2007007259A (es) 2007-08-14
BRPI0519148A2 (pt) 2008-12-30
WO2006067091A1 (en) 2006-06-29
US20080064643A1 (en) 2008-03-13
KR20070094802A (ko) 2007-09-21
JP2008524167A (ja) 2008-07-10
CA2590750A1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
CN101084240A (zh) MyD88同型二聚体化抑制剂
DE69827956T2 (de) Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
CA2699891C (en) Macrocyclic compounds as antiviral agents
Humphrey et al. Total synthesis of the serine-threonine phosphatase inhibitor microcystin-LA
US5475085A (en) Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
US6013458A (en) Reverse-turn mimetics and methods relating thereto
DE69929887T2 (de) Hepatitis c inhibitor peptide
JP5995951B2 (ja) 選択的カスパーゼ阻害剤およびその使用
Plucinska et al. Multiple binding modes for the receptor-bound conformations of cyclic AII agonists
CA2418204A1 (en) Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
EP0656907A1 (en) Conformationally restricted mimetics of reverse turns and peptides containing the same
Mona et al. Design, synthesis, and biological evaluation of CXCR4 ligands
Ede et al. Solid phase synthesis of peptide aldehyde protease inhibitors. Probing the proteolytic sites of hepatitis C virus polyprotein
Mapelli et al. Synthesis of four diastereomeric enkephalins incorporating cyclopropyl phenylalanine
JPH02300199A (ja) レトロウイルスプロテアーゼ阻害剤
US5811389A (en) Tri- and tetracyclic compounds
US6245742B1 (en) Peptide antagonists of cellular mitogenesis and motogenesis and their therapeutic use
Long et al. Global optimization of conformational constraint on non-phosphorylated cyclic peptide antagonists of the Grb2-SH2 domain
Bland et al. Potential of natural peptidic compounds as leads for novel pesticides
AU5463300A (en) Neuromedin b and somatostatin receptor agonists
CN112521459A (zh) 一种stat3抑制多肽及其制备方法和应用
Hariton-Gazal et al. Inhibition of nuclear import by backbone cyclic peptidomimetics derived from the HIV-1 MA NLS sequence
JPH08509709A (ja) Ｎ▲上α▼−メチルアルギニンを含有する血小板糖たんぱく▲ＩＩ▼ｂ／▲ＩＩＩ▼ａ抑制剤の製造方法およびそれに用いる中間体化合物
Kim et al. Theoretical analysis and prediction of catalysts for oxidative decarboxylation of melanin-concentrating hormone
Lian Development and Optimization of Protein-Protein Interaction Inhibitors by Combinatorial and Medicinal Chemistry

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1113491

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20071205

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1113491

Country of ref document: HK